Skip to content
value.today

Coya Therapeutics, Inc.

COYA
$92 Mmarket cap on Oct 26, 2026
Compare
World rank
#19,017
Revenue
$8 M
For year ending December-2025
Net income
$-21 M
-267.0% margin
SEC filing
Employees
—

Coya Therapeutics, Inc. in brief

Coya Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $92 M on 26 October 2026, which makes it the 19,017th largest listed company in the world and the 3,552nd largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $21 M. Its shares trade under the symbol COYA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Coya Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi and since their discovery multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Dr. Sakaguchi was the 2025 winner of the Nobel Prize in Physiology or Medicine. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie numerous disease states, and this cellular dysfunction is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg dysfunction is correlated with the severity and progression of serious and life-threatening conditions. These and other recent advances in the understanding of Treg biology, have made this subset of T-lymphocytes an important potential therapeutic target, which we believe may provide new treatments for serious diseases.

From the company's annual report filed with the US SEC: read the report

Coya Therapeutics, Inc. timeline

3 events, 2021–2025
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 30 December 2022; shares registered for exchange trading on 27 December 2022.
  5. 2025
  6. 💰
    Record revenue of $8 million
    FY2025, the highest of the 3 years on record.

Events of Coya Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$30 M$61 M$91 M$122 M

World rank over time

▼ down 677 places since 2026
2026-10-13: #18378#18,37820262026-10-26: #19055#19,0552026

Rank in USA: #3,436 (Oct 2026) · #3,556 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
19.7×
Price / book
2.1×
Free cash flow yield
—
Net margin (TTM)
-643.5%
Operating margin
-283.8%
Return on equity
-70.1%
Liabilities / assets
13.9%
Revenue growth
+123.9%
R&D / revenue
210.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-5M—FY21Fiscal year ending Dec 2022: revenue —, net income $-12M—FY22Fiscal year ending Dec 2023: revenue $6M, net income $-8M$6MFY23Fiscal year ending Dec 2024: revenue $4M, net income $-15M$4MFY24Fiscal year ending Dec 2025: revenue $8M, net income $-21M$8MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$8M+123.9%$-23M$-21M-267.0%
Dec 2024$4M-40.8%$-17M$-15M-419.2%
Dec 2023$6M—$-8M$-8M-133.2%
Dec 2022——$-10M$-12M—
Dec 2021——$-5M$-5M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M——$-1.27—
Dec 2024$-10M——$-0.98—
Dec 2023$-11M——$-0.79—
Dec 2022$-7M——$-4.73—
Dec 2021$-4M——$-1.89—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-30M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-7M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-6M$0MJun ’25Three months to Sep 2025: revenue $4M, net income $-2M$4MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-6M$4MDec ’25Three months to Mar 2026: revenue $0M, net income $-7M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-7M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-11M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (-93.5% on a year earlier), net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Coya Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$8 M
Operating income
$-23 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$50 M
Total liabilities
$7 M
Total equity
$43 M

As of December-2025

Top 52 institutional investors in Coya Therapeutics, Inc.#

As of Sep 30, 2026
52 institutions held 7.4 M shares (about 31.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 25.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Coya Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1DME Capital Management, LP2,335,5400 (0.00%)9.96%$12 MNov 16, 2026
2Vanguard Capital Management LLC852,751+10,531 (+1.25%)3.64%$4 MNov 13, 2026
3AIGH Capital Management LLC631,9120 (0.00%)2.69%$3 MNov 2, 2026
4Alyeska Investment Group, L.P.400,000-400,000 (-50.00%)1.71%$2 MNov 16, 2026
5CM Management, LLC400,0000 (0.00%)1.71%$2 MNov 12, 2026
6Private Management Group Inc380,876-3,341 (-0.87%)1.62%$2 MNov 4, 2026
7Marshall Wace, LLP323,849+74,056 (+29.65%)1.38%$2 MNov 13, 2026
8Prosight Management, LP229,600+59,600 (+35.06%)0.98%$1 MNov 13, 2026
9Geode Capital Management, LLC211,036-17,207 (-7.54%)0.90%$1 MNov 6, 2026
10Dimensional Fund Advisors LP169,458+13,541 (+8.68%)0.72%$1 MNov 4, 2026
11Vanguard Fiduciary Trust Co129,5510 (0.00%)0.55%$1 MNov 13, 2026
12Renaissance Technologies LLC121,800-71,186 (-36.89%)0.52%$1 MNov 12, 2026
13Prelude Capital Management, LLC101,885+555 (+0.55%)0.43%$1 MNov 16, 2026
14Jones Financial Companies Lllp100,160-10,750 (-9.69%)0.43%$1 MNov 13, 2026
15JBF Capital, Inc.100,0060 (0.00%)0.43%$1 MNov 16, 2026
16BlackRock, Inc.98,596-3,812 (-3.72%)0.42%$0 MNov 13, 2026
17Royal Bank Of Canada83,900-9,514 (-10.18%)0.36%$0 MNov 16, 2026
18State Street Corp79,8130 (0.00%)0.34%$0 MNov 12, 2026
19Prudential Financial Inc79,701New0.34%$0 MNov 16, 2026
20Morgan Stanley77,700-4,406 (-5.37%)0.33%$0 MNov 13, 2026
21Susquehanna International Group, LLP64,144+3,138 (+5.14%)0.27%$0 MNov 16, 2026
22Goldman Sachs Group Inc46,421+20,241 (+77.31%)0.20%$0 MNov 16, 2026
23Northern Trust Corp45,0720 (0.00%)0.19%$0 MNov 16, 2026
24ADAR1 Capital Management, LLC40,9000 (0.00%)0.17%$0 MNov 16, 2026
25Long Corridor Asset Management Ltd38,7660 (0.00%)0.17%$0 MNov 12, 2026
Show all 52: investors 26 to 52
Institutional investors 26 to 52 in Coya Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG34,495+1,407 (+4.25%)0.15%$0 MNov 10, 2026
27Jane Street Group, LLC28,495New0.12%$0 MNov 12, 2026
28GHP Investment Advisors, Inc.26,1710 (0.00%)0.11%$0 MOct 15, 2026
29XTX Topco Ltd21,102-20,299 (-49.03%)0.09%$0 MNov 16, 2026
30Northwestern Mutual Wealth Management Co20,6260 (0.00%)0.09%$0 MNov 13, 2026
31Axq Capital, LP15,927-3,882 (-19.60%)0.07%$0 MNov 12, 2026
32Mercer Global Advisors Inc /adv12,320New0.05%$0 MNov 16, 2026
33American Century Companies Inc11,218New0.05%$0 MNov 12, 2026
34Raymond James Financial Inc10,2250 (0.00%)0.04%$0 MNov 12, 2026
35HighTower Advisors, LLC10,0290 (0.00%)0.04%$0 MNov 10, 2026
36Charles Schwab Investment Management Inc10,0000 (0.00%)0.04%$0 MNov 16, 2026
37First Dallas Securities Inc.10,000New0.04%$0 MNov 13, 2026
38Vanguard Global Advisers, LLC5,8790 (0.00%)0.03%$0 MNov 13, 2026
39Jpmorgan Chase & Co5,004-177 (-3.42%)0.02%$0 MNov 12, 2026
40BNP Paribas Financial Markets4,7630 (0.00%)0.02%$0 MNov 12, 2026
41Bfsg, LLC3,4550 (0.00%)0.01%$0 MOct 30, 2026
42Tower Research Capital LLC (TRC)3,217New0.01%$0 MNov 16, 2026
43Rockefeller Capital Management L.P.2,0000 (0.00%)0.01%$0 MNov 13, 2026
44Allworth Financial LP1,000-12,000 (-92.31%)0.00%$0 MNov 17, 2026
45SBI Securities Co., Ltd.8200 (0.00%)0.00%$0 MOct 22, 2026
46Wells Fargo & Company/mn5000 (0.00%)0.00%$0 MNov 16, 2026
47North Star Investment Management Corp.3400 (0.00%)0.00%$0 MOct 27, 2026
48Superior Planning, LLC315—0.00%$0 MNov 12, 2026
49Arax Advisory Partners190+130 (+216.67%)0.00%$0 MNov 12, 2026
50Triumph Capital Management500 (0.00%)0.00%$0 MOct 14, 2026
51Caitong International Asset Management Co., Ltd35-6 (-14.63%)0.00%$0 MOct 29, 2026
52Barclays PLC3-110 (-97.35%)0.00%$0 MNov 6, 2026

Mutual funds holding Coya Therapeutics, Inc.#

22 funds hold shares worth $7 M (about 5.3% of the company). Since their previous reports 11 added shares and 2 sold, buying $0 M net.
Mutual funds holding Coya Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.601,117$4 M2.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.219,955$1 M0.94%<0.01%−0.1%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC108,636$1 M0.46%<0.01%+10%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors65,909$0 M0.28%0.03%+39%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP75,558$0 M0.32%<0.01%+0.6%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC33,438$0 M0.14%<0.01%+41%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP37,158$0 M0.16%<0.01%+148%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC24,066$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC14,892$0 M0.06%<0.01%+86%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,902$0 M0.05%<0.01%−18%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,246$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP13,107$0 M0.06%<0.01%+6.5%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.10,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,435$0 M0.02%0.01%+27%Jun 30, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP4,793$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP3,506$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP3,494$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP2,845$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,312$0 M<0.01%<0.01%+16%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP1,977$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP1,715$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP137$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Coya Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
Coya Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dov A. GoldsteinDirectorOption exercise+17,557$1.090$19 K27,557Form 4
filed David S. SnyderChief Financial OfficerBuy+1,800$7.190$13 K8,800Form 4
filed Arun SwaminathanChief Executive Officer, DirectorBuy+5,000$7.360$37 K10,000Form 4
filed Fred GrossmanChief Medical OfficerBuy+2,710$7.370$20 K2,710Form 4
filed Arun SwaminathanChief Executive Officer, DirectorBuy+5,000$7.340$37 K5,000Form 4
filed Ann LeeDirectorBuyindirect+1,000$3.620$4 K17,479Form 4
filed Adrian HepnerChief Medical OfficerBuy+10,000——10,000Form 4
filed Hideki GarrenDirectorBuy+2,000——2,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Coya Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.4 M
6.7% of shares · 11.89 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5.69 reverse split

Fails to deliver

  • : 2,731 shares at $3.94
  • : 190 shares at $4.25
  • : 80 shares at $4.81
  • : 617 shares at $5.18
  • : 5,020 shares at $5.04

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Coya Therapeutics, Inc. scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in financial health (2 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.1×Price to book 2.1× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median19.7×Price to sales 19.7× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year123.9%Revenue up 123.9% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.27 vs -0.98Diluted EPS -1.27 in fiscal 2025 against -0.98 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-283.8%-283.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-51.4%-51.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities8.5×Current ratio 8.51 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone6.00Z-score 6.00 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Coya Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Coya Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-283.8%-60.5%
Net margin-267.0%-68.9%
Return on equity-51.4%-61.0%
Revenue growth123.9%15.8%

2of 7on the Piotroski tests of financial strength

  • Net loss of $21 million, the 5th loss-making year in a row.
  • The share count rose 9.8% in the year.

Coya Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Coya Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue7,9463,5546,0020—
Research and development16,73511,8665,5024,4122,542
General and administrative11,4498,8867,8334,8472,312
Operating expenses30,50120,80413,9069,8124,870
Operating income−22,555−17,250−7,903−9,812−4,870
Other non-operating income (expense)1,3321,64963964−21
Income before tax−21,223−15,601−7,264−12,245—
Income tax3.1−7207240—
Net income including minority interests−21,226−14,881−7,988−12,245−4,892
Net income attributable to shareholders−21,226−14,881−7,988−12,245−4,892
Earnings per share, basic-1.27-0.98-0.79-4.73-1.89
Earnings per share, diluted-1.27-0.98-0.79-4.73-1.89
Shares, weighted average (basic)1715102.62.6
Shares, weighted average (diluted)1715102.62.6
Balance sheet
Cash and cash equivalents46,82338,34032,6275,9344,340
Other current assets3,1165,9691,0701,251244
Current assets49,93944,30841,1967,1854,584
Property, plant and equipment11396693121
Total assets49,95044,34741,2628,3964,792
Accounts payable1,0611,5881,1561,815858
Current liabilities5,8723,8245,0523,8241,148
Total liabilities6,9224,7705,62716,7891,148
Retained earnings−61,963−40,737−25,856−17,869−5,624
Shareholders' equity43,02839,57735,636−8,3943,644
Total liabilities and equity49,95044,34741,2628,3964,792
Shares outstanding2117142.6r2.6
Cash-flow statement
Share-based compensation4,2902,664872207233
Cash from operating activities−10,739−10,289−11,189−7,239−3,903
Cash from investing activities−1,165−25−543−525−137
Shares issued20,34914,004———
Cash from financing activities20,38716,02738,4259,358−341
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Coya Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 3 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 9

Coya Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K/A
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Coya Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$10 MPrivate placement after listing$10 to $50 million9equitySEC
Dec 2023$26 MPrivate placement after listing$10 to $50 million122equity, optionsSEC
Apr 2022$10 MNo. 2$10 to $50 million45debt, optionsSEC
Dec 2020$10 MNo. 1$10 to $50 million57equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Coya Therapeutics, Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2022, most often on budget/appropriations and medical/disease research/clinical labs.

Lobbying, 2022
$20 K
#1,356 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Budget/Appropriations2 reports
  • Medical/Disease Research/Clinical Labs2 reports

Lobbying firms hired in 2022

Winning Strategies Washington $20 K

Coya Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$20 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Coya Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Coya Therapeutics, Inc. compares in Biotechnology

  • Market cap$92 M · higher than 35% of 726
  • Revenue$8 M · higher than 41% of 647
  • Net margin-643.5% · higher than 7% of 408
  • Revenue growth123.9% · higher than 85% of 438
  • Price / sales19.7× · lower than 32% of 339
  • Price / book2.1× · lower than 56% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Coya Therapeutics, Inc.🇺🇸$92 M—-643.5%+123.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Coya Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Coya Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Coya Therapeutics, Inc.? Suggest a correction